Lockdown Kit containing specially compounded Povidone-iodine (PVP-I) intra-nasal sprays for each frontline care worker.
Virtual Pharmacist CHRIS provision (an industry first telehealth system supporting remote clinical care).
Environment microbe surface testing to confirm effective infection control practices, benchmarked via the PPASS-3 Tool.
A suite of proactive clinical pharmacy intervention services for consumers at high risk of COVID-19 mortality
SARS-CoV-2, the virus that causes COVID19, is thought to be transmitted through respiratory droplets, airborne transmission and physical contact from contaminated surfaces to the nose and mouth. There appears to be a large amount of virus in the nasal and throat area and it is thought that infection from these areas might to spread to the lower airway causing lung disease.
Povidone-iodine (PVP-I) is an antiseptic that has been used for the prevention or management of wound infections for over 150 years. Its antibacterial, antiviral, and antifungal properties and its safety have been well-documented. It has been previously used in intranasal preparations against MRSA infection as well as in oral preparations in laboratory studies of other viruses such as SARS-CoV, MERS-CoV, H1N1, and rotavirus with good efficacy. Clinical trials are currently underway to assess the potential use of Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel. It is thought that the use of povidone iodine nasal spray may act to decontaminate the nasal area and reduce transmission of SARS-CoV-2.
This is the only evidence based method to confirm to stakeholders (Board members through to consumers) that the facility’s environment related infection control or outbreak management procedures are effective.
The service identifies opportunities for continuous improvement in environmental cleaning and hand hygiene practices.
Exhibits high-level compliance to Quality Framework Requirements Standard 3 (3)(g); Standard 5 (3)(b); and Standard 8 (3)(e).
A proactive service that categorically helps protect residents and staff from infection, minimising health complications & staffing disruptions.
1) Our Clinical Pharmacist visits your facility and conducts agar dip-slide swabs (6 randomised test sites are completed out of 30 established benchmarked objects & surfaces).
2) The samples are placed into Choice Aged Care’s nearest incubator (Brisbane, Sydney or Melbourne).
3) Total Microbe Count is analysed 24 hours later, benchmarked via the PPASS-3 Tool and results with recommendations are submitted to management.
Enter system password for access: